Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition' episode artwork

EPISODE · Oct 9, 2025 · 23 MIN

Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'

from BiotechTV - News · host BiotechTV

Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.

Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.

NOW PLAYING

Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'

0:00 23:20

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 23 minutes long.

When was this BiotechTV - News episode published?

This episode was published on October 9, 2025.

What is this episode about?

Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!